Lorazepam
- Generic Name
- Lorazepam
- Brand Names
- Ativan, Loreev
- Drug Type
- Small Molecule
- Chemical Formula
- C15H10Cl2N2O2
- CAS Number
- 846-49-1
- Unique Ingredient Identifier
- O26FZP769L
- Background
Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.
- Indication
Lorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.
...
- Associated Conditions
- Agitation, Alcohol Withdrawal Delirium, Alcohol Withdrawal Syndrome, Anxiety, Anxiety Disorders, Chemotherapy-Induced Nausea and Vomiting, Delirium, Insomnia, Muscle Spasms, Panic Disorder, Psychogenic Catatonia, Status Epilepticus
- Associated Therapies
- Anesthetic premedication therapy
Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus
- Conditions
- Interventions
- First Posted Date
- 2013-06-05
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 434
- Registration Number
- NCT01870024
- Locations
- 🇫🇷
Département d'Anesthésie - Réanimation - SMUR - Hôpital Lariboisière, Paris, France
Promethazine vs. Lorazepam for Treatment of Vertigo
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2013-06-14
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Target Recruit Count
- 210
- Registration Number
- NCT01827293
- Locations
- 🇮🇷
Department of Neurology, Emam Hossein Hospital, Tehran, Nezam Abad, Iran, Islamic Republic of
Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)
- Conditions
- Interventions
- First Posted Date
- 2013-03-13
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 109
- Registration Number
- NCT01810458
- Locations
- 🇺🇸
Shands at the University of Florida, Gainesville, Florida, United States
The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms
- First Posted Date
- 2013-01-31
- Last Posted Date
- 2016-11-10
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 57
- Registration Number
- NCT01780519
- Locations
- 🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States
Explanation About Sleep in Post Trauma Patients
- Conditions
- Interventions
- First Posted Date
- 2012-09-12
- Last Posted Date
- 2012-10-10
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 70
- Registration Number
- NCT01684085
- Locations
- 🇮🇱
Chaim Sheba Medical Center, Tel Hashomer, Israel
Biological Basis of Individual Variation in Social Cooperation
- Conditions
- Interventions
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- Emory University
- Target Recruit Count
- 707
- Registration Number
- NCT01566539
- Locations
- 🇺🇸
Emory University 1462 Clifton Rd, Atlanta, Georgia, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
Resistance Under the Microscope
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 400
- Registration Number
- NCT01441843
- Locations
- 🇳🇱
Erasmus University Medical Center, Rotterdam, Netherlands
Developing Individualized Strategies to Prevent Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2013-11-14
- Lead Sponsor
- University of California, San Francisco
- Registration Number
- NCT01393288
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Brigham & Women's Hospital, Boston, Massachusetts, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Hydrocodone For Pain Control in First Trimester Surgical Abortion
- Conditions
- Interventions
- First Posted Date
- 2011-04-07
- Last Posted Date
- 2019-04-26
- Lead Sponsor
- Elizabeth Micks
- Target Recruit Count
- 121
- Registration Number
- NCT01330459
- Locations
- 🇺🇸
Planned Parenthood CW, Portland, Oregon, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
A Study of the Effect of LY2216684 on Lorazepam
- Conditions
- Interventions
- First Posted Date
- 2011-01-12
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT01275144
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Leeds, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.